Method of inhibiting the proliferation of T and/or B lymphocytes via dimethylarginine derivatives and lymphocytes proliferation inhibitor
US11654126B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Aug 13, 2020 |
| Grant date | May 23, 2023 |
| Priority date | — |
| Expiry date | Aug 18, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention belongs to the technical field of immunotherapy. A method of using dimethylarginine derivatives to inhibit the proliferation of lymphocyte. ADMA, SDMA, and their derivative DMGV can inhibit T cells and/or B cells proliferation in vitro by inducing mitochondrial ROS. ADMA and SDMA can induce mitochondrial ROS generation by the action of alanine-glyoxylate aminotransferase 2 (AGXT2), which converts both ADMA and SDMA into dimethylguanidino valeric acid (DMGV) in the mitochondria. The dimethylarginine dimethylamino hydrolase (DDAH) inhibitor PD404182 also inhibits T cell proliferation by allowing more ADMA and SDMA to be converted to DMGV. As a clinical relevance, DMGV effectively treated arthritis in mice which was caused by activated T cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.